Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 240

1.

Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence.

Martínez-Salamanca JI, Carballido J, Eardley I, Giuliano F, Gratzke C, Rosen R, Salonia A, Stief C.

Eur Urol. 2011 Sep;60(3):527-35. doi: 10.1016/j.eururo.2011.05.054. Epub 2011 Jun 12. Review.

PMID:
21684677
[PubMed - indexed for MEDLINE]
2.

A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M.

Eur Urol. 2012 May;61(5):994-1003. doi: 10.1016/j.eururo.2012.02.033. Epub 2012 Feb 25. Review.

PMID:
22405510
[PubMed - indexed for MEDLINE]
3.

Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report.

Liguori G, Trombetta C, De Giorgi G, Pomara G, Maio G, Vecchio D, Ocello G, Ollandini G, Bucci S, Belgrano E.

J Sex Med. 2009 Feb;6(2):544-52. doi: 10.1111/j.1743-6109.2008.01109.x. Epub 2008 Dec 2.

PMID:
19138360
[PubMed - indexed for MEDLINE]
4.

Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.

Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary KT, Mirone V, Porst H, Roehrborn CG.

Eur Urol. 2011 Oct;60(4):809-25. doi: 10.1016/j.eururo.2011.06.037. Epub 2011 Jun 29. Review.

PMID:
21726934
[PubMed - indexed for MEDLINE]
5.

Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.

Yassin A, Saad F, Hoesl CE, Traish AM, Hammadeh M, Shabsigh R.

Andrologia. 2006 Feb;38(1):1-12. Review.

PMID:
16420236
[PubMed - indexed for MEDLINE]
6.

Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.

Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, Wyndaele JJ, Melby T, Viktrup L.

Neurourol Urodyn. 2011 Mar;30(3):292-301. doi: 10.1002/nau.20999. Epub 2011 Jan 31. Review.

PMID:
21284024
[PubMed - indexed for MEDLINE]
7.

Comorbid LUTS and erectile dysfunction: optimizing their management.

Kaminetsky J.

Curr Med Res Opin. 2006 Dec;22(12):2497-506. Review.

PMID:
17265598
[PubMed - indexed for MEDLINE]
8.

Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.

Miller MS.

Ann Pharmacother. 2013 Feb;47(2):278-83. doi: 10.1345/aph.1R528. Epub 2013 Feb 5. Review.

PMID:
23386068
[PubMed - indexed for MEDLINE]
9.

Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study.

Bechara A, Romano S, Casabé A, Haime S, Dedola P, Hernández C, Rey H.

J Sex Med. 2008 Sep;5(9):2170-8. doi: 10.1111/j.1743-6109.2008.00940.x. Epub 2008 Jul 14.

PMID:
18638006
[PubMed - indexed for MEDLINE]
10.

Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.

Miner M, Rosenberg MT, Perelman MA.

Clin Ther. 2006 Jan;28(1):13-25. Review.

PMID:
16490576
[PubMed - indexed for MEDLINE]
11.

Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.

Gales BJ, Gales MA.

Ann Pharmacother. 2008 Jan;42(1):111-5. Epub 2007 Dec 19. Review.

PMID:
18094344
[PubMed - indexed for MEDLINE]
12.
13.

Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.

Wang C.

Curr Opin Urol. 2010 Jan;20(1):49-54. doi: 10.1097/MOU.0b013e328333ac68. Review.

PMID:
19887943
[PubMed - indexed for MEDLINE]
14.

BPH/LUTS and ED: common pharmacological pathways for a common treatment.

Fusco F, D'Anzeo G, Sessa A, Pace G, Rossi A, Capece M, d'Emmanuele di Villa Bianca R.

J Sex Med. 2013 Oct;10(10):2382-93. doi: 10.1111/jsm.12261. Epub 2013 Jul 22. Review.

PMID:
23875757
[PubMed - indexed for MEDLINE]
15.

Lower urinary tract symptoms and sexual dysfunction: a common approach.

Giuliano F.

BJU Int. 2008 Mar;101 Suppl 3:22-6. doi: 10.1111/j.1464-410X.2008.07494.x. Review.

PMID:
18307682
[PubMed - indexed for MEDLINE]
16.

The role of combination medical therapy in benign prostatic hyperplasia.

Greco KA, McVary KT.

Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. Review.

PMID:
19002123
[PubMed - indexed for MEDLINE]
17.

Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Gonzalez RR, Kaplan SA.

Expert Opin Drug Metab Toxicol. 2006 Aug;2(4):609-17. Review.

PMID:
16859408
[PubMed - indexed for MEDLINE]
18.

Association of lower urinary tract symptoms and erectile dysfunction: pathophysiological aspects and implications for clinical management.

Orabi H, Albersen M, Lue TF.

Int J Impot Res. 2011 May-Jun;23(3):99-108. doi: 10.1038/ijir.2011.14. Epub 2011 May 19. Review.

PMID:
21593760
[PubMed - indexed for MEDLINE]
19.

PDE5 inhibitors in the treatment of LUTS.

Speakman MJ.

Curr Pharm Des. 2009;15(30):3502-5. Review.

PMID:
19860696
[PubMed - indexed for MEDLINE]
20.

Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS.

Chung BH, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY.

Int J Impot Res. 2009 Mar-Apr;21(2):122-8. doi: 10.1038/ijir.2009.2. Epub 2009 Feb 5.

PMID:
19194451
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk